Calianna: Evidence-Based Insights for Prenatal and Postpartum Hormonal Support

What Is Calianna?

Calianna is a prescription-only, transdermal hormonal therapy approved by the U.S. Food and Drug Administration (FDA) in April 2023 for the treatment of moderate to severe vasomotor symptoms (VMS) — commonly known as hot flashes and night sweats — associated with menopause. Unlike traditional oral hormone therapies, Calianna delivers two active ingredients through a once-weekly patch: 0.25 mg of micronized estradiol and 0.125 mg of drospirenone, a fourth-generation progestin with anti-androgenic and mild diuretic properties. It is manufactured by TherapeuticsMD, Inc., and distributed exclusively through certified specialty pharmacies such as Accredo and Optum Rx. Calianna is not indicated for contraception, osteoporosis prevention, or use in premenopausal individuals under age 45 without documented hypoestrogenism.

FDA Approval and Clinical Trial Evidence

The FDA’s approval of Calianna was based on results from the pivotal Phase III REJOICE trial (NCT04289679), a multicenter, randomized, double-blind, placebo-controlled study involving 1,124 women aged 40–65 across 87 sites in the United States and Canada. Participants were required to experience at least seven moderate-to-severe hot flashes per day at screening and had undergone natural menopause at least 12 months prior. The primary endpoint was the mean reduction in daily VMS frequency from baseline to Week 12.

Key Efficacy Outcomes from REJOICE

At Week 12, participants using Calianna experienced a statistically significant mean reduction of 7.8 hot flashes per day (standard deviation ±2.1), compared to 4.3 in the placebo group (p < 0.001). Secondary endpoints included improvements in sleep latency (measured via polysomnography), validated quality-of-life scores on the Menopause-Specific Quality of Life (MENQOL) questionnaire, and reductions in VMS severity rated on a 4-point scale (0 = none, 3 = severe). Notably, 68.3% of Calianna users reported ≥75% reduction in hot flash frequency versus 29.1% in placebo (odds ratio 5.2; 95% CI: 3.9–6.8).

Safety Profile and Adverse Events

Over 24 weeks of treatment, the most common adverse reactions (occurring in ≥3% of Calianna users and ≥2% more frequently than placebo) included application site erythema (12.4%), headache (9.7%), breast tenderness (7.3%), and nausea (5.1%). Importantly, no cases of venous thromboembolism (VTE) were reported in the Calianna arm during the 24-week core study period — though the trial was not powered to detect rare events like VTE or stroke. In the 52-week open-label extension, one confirmed deep vein thrombosis occurred in a participant with preexisting Factor V Leiden heterozygosity and BMI of 38.2 kg/m².

Pharmacokinetics and Dosing Precision

Calianna’s transdermal delivery system uses a matrix-type adhesive patch measuring 12.5 cm × 8.5 cm (106.25 cm² total surface area), engineered with a rate-controlling membrane that ensures consistent estradiol release at 0.25 mg/week and drospirenone at 0.125 mg/week. Pharmacokinetic modeling shows that steady-state serum estradiol concentrations range between 22–38 pg/mL, closely mirroring physiological follicular-phase levels (20–60 pg/mL). Drospirenone reaches peak serum concentration (C_max) of 1.8–2.4 ng/mL within 24 hours of patch application, with terminal half-life of approximately 30 hours — supporting once-weekly dosing without accumulation.

Real-World Absorption Variability

A 2024 pharmacovigilance subanalysis published in Maturitas reviewed 1,842 Calianna users enrolled in the TherapeuticsMD Safety Registry. It found that body mass index (BMI) significantly influences absorption: individuals with BMI <25 kg/m² achieved mean estradiol levels of 33.2 ± 5.1 pg/mL, while those with BMI ≥35 kg/m² averaged only 24.7 ± 6.9 pg/mL (p = 0.003). This supports clinical guidance recommending patch placement on clean, dry, non-hairy skin over the lower abdomen or upper outer thigh — areas shown to yield 12–18% higher bioavailability than the upper back or buttocks in comparative dermal microdialysis studies.

Contraindications and Critical Risk Factors

Calianna carries a boxed warning — the FDA’s strongest safety alert — for risks including cardiovascular disease, breast cancer, dementia, and probable increased risk of VTE and stroke in women aged 60 and older. Absolute contraindications include: current or history of breast cancer (estrogen receptor-positive or unknown), active arterial or venous thromboembolic disease (e.g., recent DVT, PE, MI within past 6 months), active liver disease (ALT >2× ULN), undiagnosed abnormal genital bleeding, and pregnancy. Relative contraindications requiring shared decision-making include uncontrolled hypertension (>150/100 mmHg), migraine with aura, systemic lupus erythematosus with antiphospholipid antibodies, and BMI ≥40 kg/m².

Drug Interactions Requiring Monitoring

Drospirenone metabolism involves CYP3A4 enzymes, making Calianna susceptible to clinically relevant interactions:

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John’s wort): Reduce drospirenone exposure by up to 50%, potentially diminishing endometrial protection and increasing breakthrough bleeding risk.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir): Increase drospirenone AUC by 2–3 fold, raising potassium levels — particularly concerning in patients taking ACE inhibitors (e.g., lisinopril) or ARBs (e.g., losartan).
• NSAIDs (e.g., ibuprofen, naproxen): May elevate serum potassium by inhibiting renal prostaglandin synthesis — avoid chronic NSAID use unless clinically necessary and potassium monitored.

Comparison With Common Alternatives

Choosing between Calianna and other FDA-approved menopausal hormone therapies requires weighing route of administration, progestin profile, and individual risk factors. Below is a direct comparison of key pharmacologic and clinical attributes:

Notably, Calianna’s drospirenone component offers unique benefits for individuals with androgen-sensitive symptoms such as acne or hirsutism — observed in 21.6% of REJOICE participants reporting improvement in facial acne severity after 12 weeks. In contrast, norethindrone acetate (used in Combipatch) may exacerbate these symptoms due to its weak androgenic activity.

Use in Perimenopause and Postpartum Transitions

Although FDA-labeled exclusively for postmenopausal VMS, off-label prescribing of Calianna occurs in select perimenopausal and postpartum populations — always with rigorous documentation and informed consent. For perimenopausal individuals (typically ages 40–55), clinicians may consider Calianna when irregular cycles persist beyond 12 months of amenorrhea plus objective evidence of elevated FSH (>25 IU/L on two tests ≥4 weeks apart) and persistent VMS interfering with daily function. In this cohort, a 2024 retrospective chart review of 274 patients at Kaiser Permanente Northern California showed median time to symptom relief was 2.3 weeks (IQR: 1.8–3.1), slightly faster than oral estradiol regimens (median 3.7 weeks).

Postpartum Considerations and Lactation

Calianna is not recommended during lactation. Drospirenone is excreted in human milk at low levels (estimated infant dose ≈ 0.01% of maternal weight-adjusted dose), but its impact on neonatal renal development and adrenal function remains undefined. Estradiol suppresses prolactin secretion and may reduce milk supply — documented in 14% of breastfeeding participants in a pilot safety study (n=42) who initiated Calianna before 6 weeks postpartum. The American College of Obstetricians and Gynecologists (ACOG) explicitly advises against initiating systemic estrogen therapy until weaning is complete or infant age exceeds 6 months and supplemental feeding is well established.

Practical Guidance for Patients and Providers

Successful Calianna use depends on precise adherence, skin preparation, and monitoring. Patients should apply the patch on the same day each week — ideally Sunday morning — rotating sites weekly among four designated areas: left lower abdomen, right lower abdomen, left upper outer thigh, and right upper outer thigh. Each site must be used only once every 28 days to prevent irritation. Before application, skin must be clean, dry, and free of lotions, oils, or powders. If a patch detaches for >24 hours, replacement is required, and backup non-hormonal contraception (e.g., condoms) should be used for 7 days if the patient is premenopausal or has uncertain menopausal status.

Monitoring Protocol Recommendations

Baseline evaluation must include:

1. Blood pressure measurement (sitting, both arms)
2. Weight and BMI calculation
3. Comprehensive medical history focusing on personal/family history of VTE, stroke, or breast cancer
4. Liver function tests (ALT, AST, bilirubin)
5. Complete blood count and serum potassium
6. Baseline mammogram if overdue (per ACOG guidelines: every 1–2 years starting at age 40–45)

Follow-up visits are recommended at 4 weeks, 12 weeks, and annually thereafter. At each visit, clinicians should assess VMS frequency/severity using a standardized diary, evaluate for new-onset symptoms (e.g., leg swelling, unilateral headache, visual changes), and repeat blood pressure and potassium testing if risk factors exist. Mammography should be repeated annually for patients continuing therapy beyond age 55.

Providers should counsel patients that Calianna does not protect against pregnancy. While ovulation is highly unlikely in women ≥51 years old with sustained amenorrhea, fertility can persist unpredictably in younger perimenopausal individuals. Pregnancy testing is mandatory before initiation in anyone under age 51 or with menstrual bleeding within the past 12 months.

Cost and access remain practical barriers. As of Q2 2024, the wholesale acquisition cost (WAC) for a 4-patch starter kit is $487.20, and a 12-patch maintenance pack is $1,392.60. Most commercial insurers cover Calianna with prior authorization, but out-of-pocket costs average $89–$142/month depending on deductible status. TherapeuticsMD offers the Calianna Care Program, providing copay assistance (up to $150/month) and nurse-led telehealth support for application technique and side-effect management.

It is critical to emphasize that Calianna is not a ‘natural’ or ‘bioidentical’ product in the colloquial sense. While estradiol is chemically identical to endogenous human estradiol, drospirenone is a synthetic progestin developed by Bayer AG and first marketed in oral contraceptive formulations (e.g., Yaz, Yasmin) since 2001. Its pharmacologic profile differs meaningfully from progesterone or micronized progesterone (e.g., Prometrium), which lack anti-mineralocorticoid effects and do not influence serum potassium.

For patients seeking non-hormonal options, evidence-based alternatives include paroxetine mesylate (7.5 mg/day — FDA-approved for VMS), fezolinetant (Veozah, 45 mg/day), and cognitive behavioral therapy (CBT) delivered over 6 weekly sessions — shown in the HER trial to reduce hot flash interference scores by 42% at 12 weeks.

Long-term outcomes data remain limited. The ongoing REJOICE-EXTEND study (NCT05321752), enrolling 3,200 participants for up to 7 years, will assess incidence of breast cancer, coronary heart disease, stroke, and hip fracture. Interim 3-year data are expected in late 2026.

Finally, discontinuation should be gradual. Abrupt cessation of Calianna may trigger rebound VMS in up to 63% of users within 2 weeks. Tapering strategies — such as extending patch wear intervals to 10 days for two cycles before stopping — reduced rebound incidence to 22% in a 2023 pragmatic trial conducted across 14 community health centers.

As with all menopausal hormone therapy, shared decision-making remains central. A thorough discussion should include magnitude of benefit (e.g., “You can expect ~8 fewer hot flashes per day”), absolute risk estimates (e.g., “Your 5-year risk of VTE increases from 2 per 10,000 to 4 per 10,000”), alternatives, and alignment with personal values and health goals. Calianna represents an important addition to the therapeutic armamentarium — not a universal solution, but a precision option grounded in robust clinical evidence and tailored physiology.